Trial · NCT05468268
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TMS evoked potentials - TEPs changes. Analysis of cortical excitability and inhibition changes | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16) | 180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze cortical excitability and inhibition changes induced in the state of excitability/inhibition of brain circuits following the TMS impulse. The amplitude will be used as a marker of cortical excitability. |
| Primary | Connectivity Index, cortico-cortical connectivity analysis: changes in the connectivity evoked by TMS | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16) | 180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze changes in the latencies and topographical distribution of the TEPs thus providing a connectivity index. This connectivity index will be used to infer the propagation of the activity from the stimulation site to functionally connected areas. |
| Primary | TMS evoked oscillations changes | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16) | 180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze changes in responses induced by TMS in the frequency domain for the intrinsic capacity of the stimulated area to generate oscillatory activity in specific frequency bands |
| Primary | Autobiographical Memory Interview: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | The Autobiographical Memory Interview is a method of assessing autobiographical memory using a text-based analysis of transcribed autobiographical protocols. The script is segmented into internal (temporally and contextually specific) details and external (generic or semantic) details, which are then tallied. Internal scores are conceptualized as reflecting the episodic richness of the mental simulation, whereas external scores include non-episodic components of the mental simulation such as generic information, routine simulations, or verbal artifacts like repetitions. Mean changes on test scores: \[score ranges min=N/A, max= no limit, higher score=better outcome\] |
| Primary | Free and Cued Selective Recall Reminding Test - episodic memory: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Free and Cued Selective Recall Reminding Test: the three measures being evaluated include free recall (the cumulative sum of free recall from the trials; range 0-48), total recall (the cumulative sum of free recall + cued recall from the trials, range 0-48), and cue efficiency (total recall-free recall)/(48-free recall, range 0.0-1.0). Mean changes on test scores: \[higher score=better outcome\] |
| Primary | Montreal Cognitive Assessment Test - cognitive screening: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Scores on the Montreal Cognitive Assessment Test range from zero to 30. A score of 26 and higher is considered normal. If the score is below 25, the result indicates a possible cognitive impairment. Mean changes in test scores: \[higher score=better outcome\] |
| Secondary | Raven's Coloured Progressive Matrices™: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of abstract non-verbal reasoning: mean changes in test scores \[score range 0-36, higher score=better outcome\] |
| Secondary | Forward Digit Span and Reverse Digit Span: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of short and long term memory (verbal) - Mean changes in test scores \[score range 0-9, higher score=better outcome\] |
| Secondary | Spatial Span: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of short and long term memory (visuospatial) Mean changes in test scores \[score range 0-10, higher score=better outcome\] |
| Secondary | Prose Memory: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of short and long term memory - Mean changes in test scores \[score range 0-28, higher score=better outcome\]; |
| Secondary | Free And Cued Selective Reminding Test: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of short and long-term memory - Mean changes on tests scores \[Immediate: score range 0-36; Deferred: score range 0-12, higher score=better outcome\] |
| Secondary | Rey-Osterrieth Complex Figure and modified Taylor complex figures: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Deferred re-enactment of the Rey-Osterrieth Complex Figure and modified Taylor complex figure: Long-term memory evaluation Mean changes on tests scores \[score range 0-36, higher score=better outcome\] |
| Secondary | Token Test: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t4=Week 28)] | Evaluation of linguistic production - Mean changes on tests scores \[score range 0-36, higher score = better outcome\] |
| Secondary | Verbal fluency - Semantic fluency and Phonemic fluency: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Mean changes on tests scores: \[score range 0-no limits, higher score=better outcome\] |
| Secondary | Multiple Features Cancellation task: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of attention and executive function (MFCT) - Mean changes in scores on MFCT Time \[score range, min= N/A, max= no limit, higher score=worse outcome; Mean changes in scores on MFCT Accuracy \[score range min=0, max=20, higher score=better outcome\]; Mean changes in scores on MFCT False alarm \[score range min: N/A, max= no limit, high score=worse outcome\] |
| Secondary | Trail Making test (for A, B and B-A conditions): change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of attention and executive function - Mean changes on scores for each condition \[score range: min= n/a, max= no limits, higher score=worse outcome\] |
| Secondary | The Stroop Color and Word Test: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of attention and executive function - Mean changes on scores \[score ranges min=N/A, max= no limit, higher score=worse outcome\] |
| Secondary | Attentional Matrices: change in performance | Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)] | Evaluation of attention and executive function - Mean changes on scores \[score range 0-60, higher score=better outcome\] |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05468268/registered